BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

Aug 28, 2023 - 20:00

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

Read the original article

Tags:

Previous Article

BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval

Vision for future micro-optical technology based on metamaterials

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Biogen receives EMA CHMP recommendation for ALS drug Qalsody

Biogen receives EMA CHMP recommendation for ALS drug Qa...

Feb 26, 2024

STAT+: Eli Lilly CEO donates big to Mike Pence presidential super PAC

STAT+: Eli Lilly CEO donates big to Mike Pence presiden...

Aug 23, 2023

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

AD/PD 2024: TauRx’s HMTM promising despite lacking prim...

Mar 9, 2024